1. The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011;50(12):1273–1278.

2. Background: Morbidity and mortality related to cardiovascular disease in chronic kidney disease (CKD) patients is also attributed to dyslipidemia and managing the same is crucial.

3. Aim: To determine whether fluvastatin, which is mostly characterized by its pleiotropic anti-oxidant effects, has renoprotective effects in dyslipidemic patients with CKD.

4. Methods: Number of patients: 43 dyslipidemic patients with CKD. Intervention: 10, 20 or 30 mg/day fluvastatin. In the study, the renal functions as well as lipid profiles were assessed.

5. Results: With fluvastatin, there was a significant reduction in the levels of LDL (after 3 months). No change in the serum creatinine level, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), urinary liver-type fatty-acid- binding protein (L-FABP) level and urinary 8-hydroxydeoxyguanosine (8- OHdG) level in overall patients. Significant decrease in the UAE was observed in patients with microalbuminuria (baseline UAE ≥30 mg/g·creatinine; n=23) [from 2.43±0.67 to 1.98±0.80 log(mg/g·creatinine), p=0.01]. There was a significant decrease in the urinary L-FABP levels (from 1.52±0.45 to 1.26±0.43 µg/g. creatinine, p<0.01). Also, the 8-OHdG level was significantly decreased (from 13.6±9.6 to 9.8±3.8 ng/g. creatinine, p=0.043).

9. Conclusion: Fluvastatin, besides lowering lipids, reduces UAE and the urinary L-FABP level. These pleiotropic benefits offer renoprotective effects in dyslipidemic patients with CKD.